ASCO GU 2013: Relationship of hypoxia signature with variant subgroup of clear cell renal cell carcinoma (ccRCC) and its association with clinical activity on tivozanib hydrochloride
Category: Presentation
ASCO GU 2013: Efficacy and safety data from patients with advanced renal cell cancer treated with tivozanib hydrochloride after progression on sorafenib
ASCO GU 2013: Efficacy and safety data from patients with advanced renal cell cancer treated with tivozanib hydrochloride after progression on sorafenib
ASCO GU 2013: Overall survival results from a Phase III study of tivozanib hydrochloride vs sorafenib in patients with renal cell carcinoma
ASCO GU 2013: Overall survival results from a Phase III study of tivozanib hydrochloride vs sorafenib in patients with renal cell carcinoma
ESMO 2012: Detailed comparison of the safety of tivozanib hydrochloride versus sorafenib in patients with advanced/metastatic renal cell carcinoma (mRCC) from a Phase III trial
ESMO 2012: Detailed comparison of the safety of tivozanib hydrochloride versus sorafenib in patients with advanced/metastatic renal cell carcinoma (mRCC) from a Phase III trial
ESMO 2012: Patient preference for tivozanib hydrochloride or sunitinib in the treatment of metastatic renal cell carcinoma (mRCC): TAURUS study design
ESMO 2012: Patient preference for tivozanib hydrochloride or sunitinib in the treatment of metastatic renal cell carcinoma (mRCC): TAURUS study design
ESMO 2012: Tivozanib hydrochloride pharmacokinetic/pharmacodynamic analysis of blood pressure and soluble vascular endothelial growth factor receptor 2 (sVEGFR2) in patients with advanced renal cell carcinoma
ESMO 2012: Tivozanib hydrochloride pharmacokinetic/pharmacodynamic analysis of blood pressure and soluble vascular endothelial growth factor receptor 2 (sVEGFR2) in patients with advanced renal cell carcinoma
ESMO 2012: Pharmacodynamic–pharmacokinetic study of ficlatuzumab, a monoclonal antibody directed to the hepatocyte growth factor (HGF), in patients with advanced solid tumors who have liver metastases
ESMO 2012: Pharmacodynamic–pharmacokinetic study of ficlatuzumab, a monoclonal antibody directed to the hepatocyte growth factor (HGF), in patients with advanced solid tumors who have liver metastases
ESMO 2012: A randomized phase 2 study with exploratory biomarker analysis of ficlatuzumab, a humanized hepatocyte growth factor (HGF) inhibitory monoclonal antibody, in combination with gefitinib versus gefitinib alone in Asian patients with lung adenocarcinoma
ESMO 2012: A randomized phase 2 study with exploratory biomarker analysis of ficlatuzumab, a humanized hepatocyte growth factor (HGF) inhibitory monoclonal antibody, in combination with gefitinib versus gefitinib alone in Asian patients with lung adenocarcinoma
ASCO 2012: A Phase II Biomarker Assessment of Tivozanib in ONcology trial in patients (pts) with advanced renal cell carcinoma (BATON RCC)
ASCO 2012: A Phase II Biomarker Assessment of Tivozanib in ONcology trial in patients (pts) with advanced renal cell carcinoma (BATON RCC)
ASCO 2012: Final Results of a Phase Ib Study of Tivozanib and FOLFOX6 in Patients with Advanced Gastrointestinal Tumors
ASCO 2012: Final Results of a Phase Ib Study of Tivozanib and FOLFOX6 in Patients with Advanced Gastrointestinal Tumors